BACKGROUND: @entity1951 has haemodynamic as well as osmoregulatory effects, and reflects the individual stress response. @entity3488 is co-synthesized with vasopressin, directly mirroring @entity1951 levels, but is more stable in plasma and serum. Both levels are increased in @entity1 with @entity326 . @entity1729 ( @entity1729 ) are a precursor of @entity295 . Thus, we investigated circulating levels and the prognostic use of @entity3488 for the severity and outcome in @entity1 with @entity1729 . MATERIALS AND METHODS: Five hundred and forty-five consecutive @entity1 with @entity1729 and 50 healthy controls were evaluated. Serum @entity3488 levels were measured with a new chemiluminescent sandwich immunoassay. RESULTS: Of the 545 @entity1 , 373 had @entity497 ( @entity497 ), 60 acute exacerbations of @entity1030 ( @entity1030 ), 59 acute @entity3617 , 13 exacerbations of @entity565 and 40 other final diagnoses. @entity3488 levels were significantly higher in @entity1 with @entity1729 as compared to controls (P < 0.001) with highest levels in @entity1 with @entity497 . @entity3488 levels increased with increasing severity of @entity497 , as classified by the @entity55 severity index (PSI) (P < 0.001). In @entity1 who died, @entity3488 levels on admission were significantly higher as compared to levels in survivors [70.0 (28.8-149.0) vs. 24.3 (10.8-43.8) pmol L(-1), P < 0.001]. The area under the receiver operating curve (AUC) for survival was 0.75 for @entity3488 , which was significantly higher as compared to @entity1851 (AUC 0.61, P = 0.01), leukocyte count (AUC 0.59, P = 0.01) and similar to @entity1904 (AUC 0.68, P = 0.21). CONCLUSIONS: @entity3488 levels are increased with increasing severity of @entity1729 namely in @entity1 with @entity497 and unfavourable outcome. @entity3488 levels, as a novel biomarker, might be a useful tool in the risk stratification of @entity1 with @entity1729 .

Circulating levels of XXXX , a novel biomarker, in lower @entity1729 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3617 :: ('MESH:D001991', 'Disease') :: ['bronchitis'] @entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis'] @entity326 :: ('MESH:D012772', 'Disease') :: ['septic shock'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity1904 :: ('MESH:C029100', 'Chemical') :: ['procalcitonin'] @entity1951 :: ('MESH:D014667', 'Chemical') :: ['Vasopressin', 'vasopressin'] @entity497 :: ('MESH:D003147', 'Disease') :: ['CAP', 'community-acquired pneumonia'] @entity1729 :: ('MESH:D012141', 'Disease') :: ['Lower respiratory tract infections', 'LRTI'] @entity1030 :: ('MESH:D029424', 'Disease') :: ['chronic obstructive pulmonary disease', 'COPD'] @entity3488 :: ('551', 'Gene') :: ['Copeptin', 'copeptin'] @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein']
@entity3488 :: (551,Gene) :: ['copeptin']
